An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group
by
Berk M, du Plessis AD, Birkett M, Richardt D
Department of Psychiatry,
University of the Witwatersrand,
Johannesburg, South Africa.
Int Clin Psychopharmacol 1997 May; 12(3):137-40

ABSTRACT

Duloxetine hydrochloride, a mixed reuptake inhibitor of serotonin and noradrenaline, was studied in a 6 week open-label uncontrolled multicentre design at a dose of 20 mg daily both in in- and outpatients meeting DSM-III-R criteria for unipolar major depressive disorder. Seventy-nine patients took part in the study. The mean score on the 17-item Hamilton Depression Rating Scale at baseline was 24.9 (SD 4.4), decreasing to 8.5 (SD 7.8) after 6 weeks using a last observation carried forward analysis. Clinical response, defined as a 50% reduction in 17-item Hamilton Depression Rating Scale scores, occurred in 78.2% of patients, whereas remission, defined as a 17-item Hamilton Depression Rating Scale score of < or = 6, occurred in 60.3% of patients. Duloxetine hydrochloride was safe and well tolerated in this patient population.

Options
Serotonin
Noradrenaline
Milnacipran (Ixel)
Venlafaxine (Effexor)
Duloxetine (Cymbalta)
Duloxetine: hope or hype?
Duloxetine for major depression
Duloxetine (Cymbalta): structure
Duloxetine for anxious depressives
Duloxetine (Cymbalta): pharmacology
Duloxetine for pain-ridden depressives
Duloxetine, serotonin and noradrenaline
Duloxetine for stress urinary incontinence
Long-term duloxetine (Cymbalta) for depressives
Duloxetine, a balanced serotonin-noradrenaline reuptake inhibitor

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family